The FDA approved pertuzumab-dpzb (Poherdy) as the first biosimilar for its reference product Perjeta, a monoclonal antibody ...

The EMA’s recommendation follows evidence that the targeted therapy improves progression-free survival in patients whose ...

Pertuzumab-dpzb is now considered an interchangeable biosimilar to pertuzumab as part of treatment combinations in multiple ...

FDA approves 1st biosimilar to Perjeta, Poherdy, for HER2-positive breast cancer treatment, enabling pharmacy-level substitution under state law.

The U.S. Food and Drug Administration (FDA) approved Poherdy (pertuzumab-dpzb) as the first interchangeable biosimilar to ...

In terms of prognostic risk factors, HER2 positivity, BM surgical resection, and diagnosis after 2014 were associated with ...

The agreement with EirGenix grants Sandoz exclusive rights to commercialize proposed biosimilar of pertuzumab for treatment ...

HR-positive/HER2-negative breast cancer grows with estrogen or progesterone, lacking high HER2 protein levels, making hormone ...

Each episode of this 12-part journey through a disease state contains both a physician guide and a downloadable/printable patient resource. "Medical Journeys" chart a path each step of the way for ...

Poherdy is the first FDA-approved interchangeable biosimilar to Perjeta for HER2-positive breast cancer, potentially expanding access and reducing costs. Approved for use in combination with ...

Pertuzumab-dpzb is the first interchangeable biosimilar to pertuzumab, enhancing treatment accessibility for HER2-positive ...

So, I think more to come on how first line selection might evolve in the next few years depending on results from other ...